Maraviroc + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV Coinfection
Conditions
HIV Coinfection
Trial Timeline
May 18, 2011 → Mar 24, 2015
NCT ID
NCT01327547About Maraviroc + Placebo
Maraviroc + Placebo is a approved stage product being developed by Pfizer for HIV Coinfection. The current trial status is completed. This product is registered under clinical trial identifier NCT01327547. Target conditions include HIV Coinfection.
What happened to similar drugs?
1 of 2 similar drugs in HIV Coinfection were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01327547 | Approved | Completed |
| NCT00844519 | Phase 3 | Completed |
| NCT00875368 | Approved | Completed |
Competing Products
3 competing products in HIV Coinfection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VEKIRAX + EXVIERA | AbbVie | Approved | 43 |
| Boceprevir, Peg-interferon alfa 2b and Ribavirin | Merck | Phase 2 | 35 |
| Peginterferon Alfa-2 | Roche | Phase 3 | 32 |